

# Dyslipidemia/Atherosclerosis




ACS AF/SPAF CKD **Dys/Ath** NAFL/NASH HF Obesity PAD PH T1D T2D VT



**Chung I Choi**  
Senior Director,  
Atherosclerosis

Chung I received her B.A. from University of California, Berkeley in Biochemistry and Political Economics, and brings 20 years of biotechnology and pharmaceutical consulting experience to her clients. Her excellent communication skills, solid business acumen and command of analytical methods enable her to support a wide range of pharma teams. Chung I has been a leader of CVrg's atherosclerosis team since 2008.



**Aubrey Ledford, Ph.D.**  
Disease Area Manager

Aubrey received her Ph.D. in Molecular and Cellular Pathobiology from Wake Forest University.

She brings over 10 years of pharmaceutical industry experience to CVrg including pipeline and clinical trial analysis, in-depth KOL research, conference analysis, translational research, and direct support of clinical trials. Her experience reaches all phases of product development, enabling her to understand the needs and priorities of CVrg clients.



## CVrg Market Strategies™ report

**Dyslipidemia/Atherosclerosis, 2018–2027** is a cutting-edge detailed market research report with unmatched scope, depth, and accuracy. This best-in-class resource provides a highly granular assessment of new product development, emerging trends, unmet needs, epidemiology, current treatment and market forecasts. KOL comments, SWOTs, clinical trial tracking, estimations of launch dates and target patient populations are included for products ≥Ph 2 along with regional coverage of USA, EU5, and Japan. Fresh new data and analytical observations gained throughout the year in Dys/Ath from CVrg Sentinel, Conference, Insights, and Advisory research are also included.

## CVrg Sentinel™ monthly updates

CVrg continuously monitors how new scientific, clinical, regulatory and market developments are changing the commercial potential of Dys/Ath assets. This monthly delivery informs clients about what is happening in the marketplace and how it might affect their products.

## CVrg Conference™ expert coverage

CVrg keeps abreast of cutting edge clinical data by attending cardio-metabolic congresses such as ACC, ESC, and AHA. Our experts carefully analyze the new data presented and deliver incisive, presentation-style reports informing subscriber organizations about what's new, what's important, and why.

## CVrg KOL Insights™ primary research

CVrg experts conduct primary research with KOLs in Dys/Ath, using their critical eyes to evaluate emerging trends, pipeline products and implications for the field. Clients may review and add to our "omnibus" discussion guides and receive detailed reports and presentations focused on answering the most pressing issues they face today.

## CVrg Advisory™ answers to your ad-hoc inquiries

CVrg is uniquely positioned to deliver quick, thorough and reliable answers to non-proprietary questions in Dys/Ath drug markets. We are immediately equipped with comprehensive data and put our best methodologies and efforts behind each inquiry so clients receive the most accurate insight possible within a given timeframe.